News

On the NHS, costs are set through commercial arrangements and are not always public, while in private practice the listed prices for...

Since both contain semaglutide, their side-effect profiles are similar — most commonly nausea, vomiting, and diarrhoea. Wegovy uses a...

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different approaches Although both Wegovy and Contrave are prescribed for weight management, they work in completely different ways. Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces ap

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why these medicines are combined Doctors frequently prescribe Wegovy (semaglutide) alongside metformin, particularly in

Combination weight loss medications aren’t routine in UK services because evidence for stacking treatments is limited and side-effect...

Combination weight loss medications aren’t routine in UK services because evidence for stacking treatments is limited and side-effect...

The price of ‘King Kong’ weight loss jab Mounjaro will almost triple from September...

You may have seen the news today... The price of ‘King Kong’ fat jab Mounjaro will almost triple from September adding a potential £2,704 a year to the cost of the drug.

You may have seen the news today... The price of ‘King Kong’ fat jab Mounjaro will almost triple from September adding a potential £2,704 a year to the cost of the drug.

Weight loss medicines have always been subject to close regulatory scrutiny in the UK. Questions about safety, long-term outcomes, and marketing claims have historically made approvals slow and complex. The arrival of Wegovy, however, marked a significant shift. With strong trial data and NICE endorsement, semaglutide has not only reshaped consumer demand but also influenced how regulators and policymakers approach the entire category of weight loss pharmaceuticals. Changes i

Pharmaceutical breakthroughs rarely stand alone. Behind every new treatment lies a network of research teams, healthcare providers, regulators, and increasingly, technology firms. Strategic collaborations are the glue that connects these players, accelerating development and improving delivery. With the arrival of Wegovy, the importance of collaboration in the UK weight loss sector has become even clearer. The medicine’s impact has extended beyond patients and clinics, sparki

Pharmaceutical breakthroughs rarely stand alone. Behind every new treatment lies a network of research teams, healthcare providers,...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. New weight loss pill...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. New weight loss pill...

The marketing of weight loss products in the UK has changed dramatically in recent years. Once dominated by glossy ads, celebrity...

The marketing of weight loss products in the UK has changed dramatically in recent years. Once dominated by glossy ads, celebrity...

The weight-loss pharmaceutical industry in the UK has long been a challenging space for investors. Products like orlistat offered modest returns, and consumer interest often shifted toward lifestyle fads rather than prescriptions. But Wegovy has changed the calculus. With clinical results that set a new benchmark and NHS endorsement signalling credibility, investors are paying closer attention. Capital is flowing into the sector at levels not seen before, reshaping expectatio

"Only 8 out of 42 health boards are offering Mounjaro... so what's the hold up?" You've guessed it - Mounjaro is in the news again due to...

"Only 8 out of 42 health boards are offering Mounjaro... so what's the hold up?" You've guessed it - Mounjaro is in the news again due to the latest controversy of the King-Kong weight loss jab being touted as 'available' on the NHS.... so what exactly is going on? Why are thousands of patients still waiting for a treatment that could transform their lives? Mounjaro was meant to be rolled out across the NHS in England from 23 June for those with the highest clinical need unde

An article today has been released by The Guardian claiming that, as demand for these weight loss medications soar, the supply chain is being put under intense pressure in terms of being able to supply enough of these medications. This goes hand in hand with advice from the MHRA to ensure the products you buy are genuine.